Deneke Matthew G, Arguedas Miguel R
Department of Internal Medicine University Of Alabama at Birmingham, Birmingham, AL 35294, USA.
Expert Rev Vaccines. 2003 Oct;2(5):661-72. doi: 10.1586/14760584.2.5.661.
Hepatitis A vaccines have demonstrated a high degree of immunogenicity and an excellent safety profile. Immunization of certain populations and patient subgroups is recommended according to specific epidemiological and clinical factors, such as a greater likelihood of acquisition of infection or concerns regarding the risk of development of fulminant hepatitis and death. Therefore, the economic implications of routine and/or targeted vaccination programs in the general population and high-risk individuals have been examined. In this manuscript, the available data from the literature regarding the cost-effectiveness of hepatitis vaccination programs in healthy individuals and in those with chronic liver disease are reviewed.
甲型肝炎疫苗已显示出高度的免疫原性和出色的安全性。根据特定的流行病学和临床因素，如感染风险较高或对暴发性肝炎和死亡风险的担忧，建议对某些人群和患者亚组进行免疫接种。因此，已经对普通人群和高危个体中常规和/或有针对性的疫苗接种计划的经济影响进行了研究。在本手稿中，回顾了文献中有关健康个体和慢性肝病患者中肝炎疫苗接种计划成本效益的现有数据。
